Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Crizotinib |
Trade Name | Xalkori |
Synonyms | PF-02341066 |
Drug Descriptions |
Xalkori (crizotinib), inhibits ALK kinase, ALK fusion proteins, c-Met, ROS1 fusion proteins, and MST1R (RON), resulting in growth inhibition of tumor cells (PMID: 26951079, PMID: 22617245). Xalkori (crizotinib) is FDA approved for use in patients with ALK or ROS1 positive (rearrangements and fusions) non-small cell lung cancer, and in pediatric patients 1 year and older and young adults with relapsed or refractory, ALK-positive systemic anaplastic large cell lymphoma (FDA.gov). |
DrugClasses | ALK Inhibitor 23 MET Inhibitor 51 RON Inhibitor 10 ROS1 Inhibitor 14 |
CAS Registry Number | 877399-52-5 |
NCIT ID | C74061 |